Ginkgo Bioworks Holdings Inc. (DNA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ginkgo Bioworks Holdings Inc. (DNA:NYSE), powered by AI.

Current Price
$6.90
P/E Ratio
-0.7
Market Cap
358M
Sector
Healthcare
What is the Ginkgo Bioworks Holdings Inc. stock price forecast?

Ginkgo Bioworks Holdings Inc. is currently trading at $6.90. View real-time AI analysis on Alpha Lenz.

What is Ginkgo Bioworks Holdings Inc. insider trading activity?

View the latest insider trading data for Ginkgo Bioworks Holdings Inc. on Alpha Lenz.

What is Ginkgo Bioworks Holdings Inc.'s P/E ratio?

Ginkgo Bioworks Holdings Inc.'s P/E ratio is -0.7.

Ginkgo Bioworks Holdings Inc.

$6.90
NYSEDNA
Ask about Ginkgo Bioworks Holdings Inc.'s future dividend policy...
Alpha Chat Insight

Ginkgo Bioworks Holdings Inc. trades at a P/E of -0.7 (undervalued) with modest ROE of -60.3%.

Ask for details

Company Overview

Ginkgo Bioworks Holdings Inc. is a pioneering company in the field of synthetic biology, focusing on the design and growth of bespoke organisms. Its primary function is to engineer biological processes to produce custom organisms that can be utilized across numerous industries, including agriculture, pharmaceuticals, food, and biofuels. Notably, the company's platform allows for the programming of cells, enabling innovations that can drive efficiencies and advancements in those sectors. Ginkgo Bioworks stands out due to its unique business model, which leverages the power of genetic coding to develop sustainable solutions and innovative products for its clients. The company operates a "cell programming" platform, akin to a computer operating system, which allows it to execute complex biological designs at scale. This role places Ginkgo Bioworks at the forefront of the biotechnology sector, as it seeks to revolutionize how biological resources are utilized and managed. With its headquarters in Boston, Massachusetts, Ginkgo is positioned as a key player in the global push towards a more sustainable bioeconomy.

CEODr. Jason Kelly Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees834

Company Statistics

(FY 2024)

Profile

Market Cap$358.07M
Revenue$227.04M
Shares Out0.00
Employees834

Margins

Gross80.38%
EBITDA-168.35%
Operating-214.82%
Pre-Tax-241.15%
Net-240.94%

Valuation

P/E-0.65
P/B0.50
EV/Sales1.58
EV/EBITDA-0.69
P/FCF-0.94

Growth (CAGR)

Rev 3Yr-10.23%
Rev 5Yr33.18%
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-35.96%
ROE-60.34%
ROIC-35.98%

Financial Health

Cash & Cash Equivalents$561.57M
Net Debt$99.82M
Debt/Equity92.37%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Ginkgo Bioworks Holdings Inc. (Healthcare) Stock Forecast & Analysis $6.90 | Alpha Lenz